Delay to Australia and European Union mutual recognition
This article was originally published in Clinica
The March election of a new government in Australia has made it difficult to predict when the proposed medical device mutual recognition agreement between Australia and the European Union will be implemented. The MRA was due to come into force on January 1st this year (see Clinica No 676, p 7). Agreement has now been reached on the technical content and the way is clear for the MRA to proceed, reports the Australian Therapeutic Device Bulletin. Officials are scheduled to meet in Brussels during May to initial the agreement. A number of changes to Australia's Therapeutic Goods Act will be required before the MRA can finally be implemented.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.